Form 4: Candel Therapeutics Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Seshu Tyagarajan, Chief Technology Officer of Candel Therapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.
Summary
- On January 8, 2025, Seshu Tyagarajan, the Chief Technology Officer of Candel Therapeutics, sold 14,545 shares of common stock at a price of $8.2182 per share.
- The sale was executed to cover tax withholding obligations associated with the vesting and settlement of restricted stock units, as per the company's mandatory sell-to-cover policy.
- Following the transaction, Tyagarajan directly owns 111,112 shares of Candel Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (sale of shares to cover taxes) and doesn't contain information that would significantly sway investor sentiment positively or negatively.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives and are generally not indicative of the executive's sentiment about the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 01/08/2025 | Date of the transaction: Seshu Tyagarajan sold shares of Candel Therapeutics common stock. |
| 01/10/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.